Vaccination against COVID-19 for patients with primary immunodeficiency and hereditary angioedema: the position paper of the Russian Association of Allergology, Clinical Immunology, and the National Association of Experts in Primary Immunodeficiencies

Cover Page

Cite item

Full Text

Abstract

Since the end of 2019, the whole world has been suffering from the Corona virus-19 (COVID-19) pandemic due to the potentially severe acute respiratory infection caused by the SARS-CoV-2 virus. To date, the infection has led to more than 4 million deaths worldwide, and >140 thousand deaths in Russia. Vaccination against COVID-19 plays a key role in stopping the pandemic. According to the existing experience in infection prevention, mass vaccination will reduce the virus’s expansion and the risk of vaccine-resistant strains developing. In the context of COVID-19, the question of the feasibility and safety of vaccination for patients with primary immunodeficiency and hereditary angioedema arises. The Russian Association of Allergists, Clinical Immunologists, and the National Association of Experts in Primary Immunodeficiencies have developed and approved a position paper on the vaccination for patients with primary immunodeficiency and hereditary angioedema against COVID-19.

This position paper provides answers to key questions regarding vaccination for patients with these diseases.

About the authors

Natalya I. Ilyina

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia

Email: instimmun@yandex.ru
ORCID iD: 0000-0002-3556-969X
SPIN-code: 6715-5650

MD, Dr. Sci. (Med.), Professor

Russian Federation, 24 Kashirskoe Shosse, Moscow, 115522

Irina V. Kondratenko

Russian Children’s Clinical Hospital

Email: ikondratenko@rambler.ru
ORCID iD: 0000-0003-4834-4075
SPIN-code: 3163-1356

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Elena A. Latysheva

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia; Pirogov Russian National Research Medical University

Email: ealat@mail.ru
ORCID iD: 0000-0002-1606-205X
SPIN-code: 2063-7973

MD, Dr. Sci. (Med.)

Russian Federation, 24 Kashirskoe Shosse, Moscow, 115522; Moscow

Tatiana V. Latysheva

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia; Moscow State University of Medicine and Dentistry named after A.I. Evdokimov

Email: tvlat@mail.ru
ORCID iD: 0000-0003-1508-0640
SPIN-code: 8929-7644

MD, Dr. Sci. (Med.), Professor

Russian Federation, 24 Kashirskoe Shosse, Moscow, 115522; Moscow

Irina A. Manto

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia

Author for correspondence.
Email: irina.manto@yandex.ru
ORCID iD: 0000-0001-6432-394X
SPIN-code: 7944-5159

MD

Russian Federation, 24 Kashirskoe Shosse, Moscow, 115522

Evgeniya V. Nazarova

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia

Email: ev.nazarova@nrcii.ru
ORCID iD: 0000-0003-0380-6205
SPIN-code: 4788-7407

MD, Cand. Sci. (Med.)

Russian Federation, 24 Kashirskoe Shosse, Moscow, 115522

Daria S. Fomina

Сlinical State Hospital № 52; The First Sechenov Moscow State Medical University (Sechenov University)

Email: daria.s.fomina@gmail.com
ORCID iD: 0000-0002-5083-6637
SPIN-code: 3023-4538

MD, Cand. Sci. (Med.)

Russian Federation, Moscow; Moscow

Musa R. Khaitov

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia; Pirogov Russian National Research Medical University

Email: mr.khaitov@nrcii.ru
ORCID iD: 0000-0003-4961-9640
SPIN-code: 3199-9803

MD, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences

Russian Federation, 24 Kashirskoe Shosse, Moscow, 115522; Moscow

Anna Yu. Shcherbina

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Email: shcher26@hotmail.com
ORCID iD: 0000-0002-3113-4939
SPIN-code: 6759-0031

MD, Dr. Sci. (Med.), Professor Member of the Russian Academy of Sciences

Russian Federation, Moscow

References

  1. Bousfiha A, Jeddane L, Picard C, et al. Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification. J Clin Immunol. 2020;40(1):66–81. doi: 10.1007/s10875-020-00758-x
  2. Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2019 update on the classification from the international union of immunological societies expert committee. J Clin Immunol. 2020;40(1):24–64. doi: 10.1007/s10875-019-00737-x
  3. World Health Organisation. Coronavirus [Internet]. Available from: https://www.who.int/health-topics/coronavirus. Accessed: Aug 28, 2021.
  4. Wikipedia. Template: COVID-19 pandemic data [Internet]. Available from: https://en.wikipedia.org/wiki/Template:COVID-19_pandemic_data. Accessed: Aug 28, 2021.
  5. World Health Organisation. Coronavirus disease (COVID-19): vaccines [Internet]. Available from: https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-vaccines. Accessed: Aug 28, 2021.
  6. Goudouris ES, Pinto-Mariz F, Mendonça LO, et al. Outcome of SARS-CoV-2 Infection in 121 patients with inborn errors of immunity: a cross-sectional study. J Clin Immunol. 2021;1–11. doi: 10.1007/s10875-021-01066-8
  7. Goldacker S, Draeger R, Warnatz K, et al. Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol. 2007;124(3):294–303. doi: 10.1016/j.clim.2007.04.011
  8. Pedersen G, Halstensen A, Sjursen H, et al. Pandemic № CD4+ Th1-cell responses in hypogammaglobulinaemic patients: four case reports. Scand J Immunol. 2011;74(2):210–218. doi: 10.1111/j.1365-3083.2011.02561.x
  9. Rezaei N, Siadat SD, Aghamohammadi A, et al. Serum bactericidal antibody response 1 year after meningococcal polysaccharide vaccination of patients with common variable immunodeficiency. Clin Vaccine Immunol. 2010;17(4):524–528. doi: 10.1128/CVI.00389-09
  10. Hanitsch LG, Löbel M, Mieves JF, et al. Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency. Vaccine. 2016;34(21):2417–2423. doi: 10.1016/j.vaccine.2016.03.091
  11. Paroli M, Accapezzato D, Francavilla V, et al. Long-lasting memory-resting and memory-effector CD4+T cells in human X-linked agammaglobulinemia. Blood. 2002;99(6):2131–2137. doi: 10.1182/blood.V99.6.2131
  12. IPOPI. Vaccination against SARS-COV-2 (COVID-19) for patients with PID [Internet]. Available from: https://ipopi.org/latest-news-on-covid-19-and-pid-1/. Accessed: Aug 28, 2021.
  13. Marciano BE, Huang CY, Joshi G, et al. BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J Allergy Clin Immunol. 2014;133(4):1134–1141. doi: 10.1016/j.jaci.2014.02.028
  14. Shearer WT, Fleisher TA, Buckley RH, et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol. 2014;133(4):961–966. doi: 10.1016/j.jaci.2013.11.043
  15. Shaghaghi M, Shahmahmoodi S, Abolhassani H, et al. Vaccine-derived polioviruses and children with primary immunodeficiency, Iran, 1995–2014. Emerg Infect Dis. 2016;22(10):1712–1719. doi: 10.3201/eid2210.151071
  16. The State Register of Medicines. Registration certificate. Instructions for the KoviVak vaccine (inactivated whole-virion concentrated purified coronavirus vaccine) [Internet]. (In Russ). Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=2b6c0483-705d-4b51-a722-2b954a9f918d&t=. Accessed: Aug 28, 2021.
  17. The State Register of Medicines. Registration certificate. Instructions for the Gam-COVID-Vac vaccine (Combined vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus) [Internet]. (In Russ). Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=7d85c1ea-a7f8-43e5-8975-a4827ee5d88a&t=. Accessed: Aug 28, 2021.
  18. The State Register of Medicines. Registration certificate. Instructions for the EpiVacCorona vaccine (A vaccine based on peptide antigens for the prevention of COVID-19 [Internet]. (In Russ). Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=35c6fdb8-821b-4f69-b566-f6245ad1f437&t=. Accessed: Aug 28, 2021.
  19. The State Register of Medicines. Registration certificate. Instructions for the drug Sputnik Light (Vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus [Internet]. (In Russ). Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=bd9750c9-178d-47cb-81e0-5e532219eebb&t=. Accessed: Aug 28, 2021.
  20. Eibl MM, Wolf HM. Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities. Immunotherapy. 2015;7(12):1273–1292. doi: 10.2217/IMT.15.74
  21. Hagin D, Freund T, Navon M, et al. Immunogenicity of pfizer-biontech COVID-19 vaccine in patients with inborn errors of immunity. J Allergy Clin Immunol. 2021;148(3):739–749. doi: 10.1016/j.jaci.2021.05.029
  22. Ameratunga R, Longhurst H, Steele R, et al. Common variable immunodeficiency disorders, T cell responses to SARS-CoV-2 vaccines and the risk of Chronic COVID-19. J Allergy Clin Immunol Pract. 2021;S2213-2198(21):00702–00709. doi: 10.1016/j.jaip.2021.06.019
  23. Temporary methodological recommendations. The procedure for vaccination of the adult population against COVID-19. Moscow; 2021. 50 p. (In Russ).
  24. Latysheva TV, Latysheva EA, Manto IA, Kostinova AM. Vaccination of patients with primary immunodeficiency: a modern view of the problem. Russian Journal of Allergy. 2017;14(3):19–26. (In Russ).
  25. Bliznec EA, Viktorova EA, Vishneva EA, et al. Hereditary angioedema. Clinical recommendations. Russian Journal of Allergy. 2021;18(2):77–114. (In Russ). doi: 10.36691/RJA1447

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Pharmarus Print Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies